NEW YORK (GenomeWeb News) – CombiMatrix today said that Pathology, Inc. will market and distribute its chromosomal microarray tests for "products of conception" testing in designated areas in the US.

Products of conception testing enables physicians to better determine if there is a genetic cause behind a miscarriage or multiple events, said Irvine, Calif.-based CombiMatrix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.